Geneseq Biosciences was founded by Ryan Van Laar Ph.D., a translational genomics scientist with over 20 years of experience in designing, validating and clinically performing cancer tests.
Dr Van Laar has over 25 peer-reviewed publications, international patents, and has been involved in multiple FDA approvals of novel & proprietary genomic assays.
Before founding Geneseq Biosciences, he was Vice President of Research & Operations and Laboratory Director for Signal Genetics, based in New York, NY and Little Rock, AR, USA.
Australian Clinical Labs.
In 2018, Australian Clinical Labs and Geneseq Biosciences formed a partnership to bring the first non-invasive melanoma test to market under the trademark Melaseq™.
Clinical Labs is the largest pathology provider to public hospitals in Australia and one of the top choices amongst private practices across the country. With over 90 NATA accredited laboratories and 900 collection sites nation-wide, the company performs around 8 million episodes a year for a range of clients including doctors, specialists, patients, hospitals and corporate clients.
Clinical Labs is a leader in molecular testing and new technologies and employs over 3,800 employees including more than 90 highly respected and experienced pathologists.
- For more information see: www.clinicallabs.com.au
Geneseq values the contributions of our commercial partners: